Multiple needs of breast and prostate cancer survivors.
SEASONS: A Prospective Study to Assess the Physical, Psychosocial, Spiritual, and Financial Needs of Breast and Prostate Cancer Survivors
A mock clinical pathway development simulation was conducted to make transparent the process of developing consensus-driven, evidence-based clinical pathways in oncology.
Cost-effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients with Metastatic Non-small Cell Lung Cancer with EGFR Exon 19 Deletion Mutations
Researchers developed a decision model to compare the cost-effectiveness of treatments for patients with EGFR-positive metastatic non–small cell lung cancer.
George Dahlman responds to a viewpoint on chemotherapy drug shortages by detailing policy measures that have been put in place to help address this issue.
Yoram Unguru, MD, MS, MA addresses the pervasive problem of drug shortages in cancer care and what is being done to resolve the issue.
Development and Implementation of De Novo Clinical Decision Support Rules at a Tertiary Cancer Center
The authors detail the development of a set of decision support rules for application within a major academic medical center and across its affiliated community satellite sites.
Health Care Use and Costs Among Medicare Patients With Chronic Obstructive Pulmonary Disease Treated With Short-Acting Beta Agonists or Long-Acting Beta Agonists
Researchers report the benefits of COPD treatment with long-acting beta agonists.
Authors examine different cost control levers the government could use to affect drug pricing and have an impact on treatments selected within clinical pathways.
Effect of Route of Bortezomib Administration on Treatment Outcomes in Previously Untreated Patients with Multiple Myeloma: A Retrospective Analysis from US Community Oncology Practices
Researchers tested Bortezomib Administration on Treatment Outcomes in patients with myeloma.
ASCO Policy Statement on Clinical Pathways in Oncology Represents Great Progress for Clinical Pathways
Winston Wong, PharmD, explains how the recent policy statement released by the American Society of Clinical Oncology represents a significant step forward for clinical pathways as a whole.